In this cohort study of 5015 patients who were treated with CDK4/6 inhibitors, PARP inhibitors, or select TKIs between 2008 and 2024, incidence and rates of progressive kidney dysfunction were higher among treated patients relative to a matched cancer-free cohort. This evidence concerns the gene CDK4 and cancer.